Loading...
Loading...
Recent Nature papers showcase two agentic AI scientific assistants—Google’s Gemini-based Co-Scientist and FutureHouse’s Robin—that accelerate hypothesis generation and drug-repurposing by synthesizing vast literature and calling external tools. Co-Scientist stages and refines ideas with human oversight, while Robin adds the ability to evaluate specific experimental data and mine cross-domain links for non-obvious drug–target matches. Demonstrated in acute myeloid leukemia and macular degeneration tasks, both prioritize surfacing testable, plausible, and safe hypotheses rather than replacing scientists. Alongside public perceptions that brand AI systems by persona, these developments highlight a trend toward tool-integrated, human-in-the-loop AI that scales discovery while guarding against hallucination.
Google showcased agent-driven features at I/O 2026, including a full operating system assembled in 12 hours using Gemini agents (93 sub-agents, ~2.6 billion tokens, under $1,000 in credits). Gemini 2.5 Flash’s high throughput enabled rapid parallel agent work, while Gemini Spark offers managed, private-cloud agent hosting. Search is becoming proactive and conversational with agentic reminders and intent-aware autocomplete. New commerce protocols let agents complete purchases end-to-end—DoorDash demoed an autonomous coffee order—raising both convenience and privacy questions. Regional-language responses (Haryanvi) and developer tools like Antigravity and Stitch powered real-world apps (Work Onward) for multilingual job postings, highlighting easier access for builders.
Nature published two papers describing agentic AI scientific assistants aimed at accelerating hypothesis generation and drug-target repurposing. Google’s Co-Scientist, built on Gemini, runs literature searches, stages hypotheses in a tournament, uses Reflection and Evolution agents to refine ideas, and keeps humans ‘in the loop’ for judgment. FutureHouse’s Robin focuses on combinatorial synthesis, mining cross-domain literature and biological experiment data to propose non-obvious connections and known drugs for new targets; it can evaluate specific experimental data classes. Both systems target literature overload to surface testable, plausible, and safe hypotheses—demonstrated on acute myeloid leukemia and macular degeneration—rather than replace scientists, and emphasize tool integration to avoid hallucinations.
Nature published two papers describing AI “science assistants” aimed at helping researchers generate and test hypotheses, particularly for drug retargeting. Google’s Co-Scientist is positioned as a “scientist in the loop” tool that relies on regular human judgement, while nonprofit FutureHouse trained a system capable of evaluating biological data from specific experiment classes. Both systems are agentic assistants that call external tools to process large volumes of scientific information rather than replace scientists; Microsoft has taken a similar tool-based approach and OpenAI has instead tuned an LLM for biology. The work matters because it scales data synthesis and hypothesis generation in life sciences, potentially speeding discovery while preserving human oversight.
A Reddit user asked a playful comparison mapping major AI systems to classroom archetypes: Gemini as the professor, Claude as a neurotic introvert, ChatGPT as the popular student whose homework everyone copies, and GitHub Copilot as the eager but often wrong classmate. The post invited others to suggest which persona fits Meta AI. While lighthearted, the framing highlights how public perception differentiates AI brands by reliability, behavior, and role—important signals for developers, product teams, and marketers. Such cultural metaphors influence user trust and positioning in the competitive AI landscape dominated by OpenAI, Google, Anthropic, Microsoft/GitHub, and Meta.